Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
4
×
biotech
4
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
4
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
4
×
wisconsin blog main
wisconsin top stories
clinical trials
alder biopharmaceuticals
calcitonin gene-related peptide
eli lilly
eptinezumab
erenumab
fda
fremanezumab
galcanezumab
migraine research foundation
novartis
teva pharmaceutical
What
drug
new
4
×
approval
class
drugs
fda
migraine
won
advantages
amgen
arguments
bar
big
bio
brings
candidates
cholesterol
commercialized
companies
competitors
decades
developed
expect
expensive
faces
financial
foe
gamble
gets
head
healthcare
hint
inhibitors
known
lowering
make
market
medco’s
medicines
meeting
Language
unset
Current search:
national
×
biotech
×
new
×
" texas top stories "
×
amgen
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines